A detailed history of Nuveen Asset Management, LLC transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 204,821 shares of TNGX stock, worth $835,669. This represents 0.0% of its overall portfolio holdings.

Number of Shares
204,821
Previous 205,270 0.22%
Holding current value
$835,669
Previous $1.76 Million 10.45%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.36 - $11.93 $3,304 - $5,356
-449 Reduced 0.22%
204,821 $1.58 Million
Q2 2024

Aug 09, 2024

SELL
$6.66 - $10.15 $952,819 - $1.45 Million
-143,066 Reduced 41.07%
205,270 $1.76 Million
Q1 2024

May 13, 2024

SELL
$7.51 - $12.88 $534,787 - $917,184
-71,210 Reduced 16.97%
348,336 $2.77 Million
Q4 2023

Feb 14, 2024

BUY
$6.52 - $12.01 $1.55 Million - $2.86 Million
238,077 Added 131.19%
419,546 $4.15 Million
Q3 2023

Nov 14, 2023

BUY
$2.93 - $11.26 $30,020 - $115,369
10,246 Added 5.98%
181,469 $2.04 Million
Q2 2023

Aug 14, 2023

BUY
$2.67 - $4.7 $25,204 - $44,368
9,440 Added 5.83%
171,223 $568,000
Q1 2023

May 15, 2023

SELL
$3.76 - $8.06 $25,492 - $54,646
-6,780 Reduced 4.02%
161,783 $639,000
Q4 2022

Feb 14, 2023

BUY
$3.41 - $8.29 $18,287 - $44,459
5,363 Added 3.29%
168,563 $1.22 Million
Q3 2022

Nov 14, 2022

SELL
$3.25 - $5.46 $435 - $731
-134 Reduced 0.08%
163,200 $591,000
Q2 2022

Aug 15, 2022

BUY
$3.86 - $8.01 $459,552 - $953,630
119,055 Added 268.87%
163,334 $740,000
Q1 2022

May 16, 2022

BUY
$7.01 - $10.94 $310,395 - $484,412
44,279 New
44,279 $338,000

Others Institutions Holding TNGX

About Tango Therapeutics, Inc.


  • Ticker TNGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,067,296
  • Market Cap $359M
  • Description
  • Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...
More about TNGX
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.